Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heart Failure
100%
Worsening Heart Failure
100%
Early Mortality
100%
Sotagliflozin
100%
Cardiovascular Mortality
28%
Placebo
28%
Type 2 Diabetic Patients
28%
All-cause Mortality
14%
Left Ventricular Ejection Fraction
14%
Estimated Glomerular Filtration Rate
14%
Subgroup Analysis
14%
Hospitalization
14%
Proportional Hazards Model
14%
Receptor Agonist
14%
Diarrhea
14%
Cardiovascular Events
14%
Heart Failure Hospitalization
14%
Heart Failure Trials
14%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
14%
Mineralocorticoid Receptor
14%
Sodium-glucose Cotransporter
14%
Treatment Comparison
14%
Urgent Care
14%
HF Hospitalization
14%
Failure Effects
14%
Medicine and Dentistry
Congestive Heart Failure
100%
Post-Hoc Analysis
100%
Sotagliflozin
100%
Cardiovascular System
42%
Placebo
28%
Patient with Type 2 Diabetes
28%
Glomerular Filtration Rate
14%
All Cause Mortality
14%
Heart Left Ventricle Ejection Fraction
14%
Proportional Hazards Model
14%
Amino Terminal Sequence
14%
Diarrhea
14%
Brain Natriuretic Peptide
14%
Subgroup Analysis
14%
Sodium Glucose Cotransporter
14%
Mineralocorticoid Receptor
14%
Urgent Care
14%
Nursing and Health Professions
Congestive Heart Failure
100%
Post Hoc Analysis
100%
Sotagliflozin
100%
Placebo
28%
Patient with Type 2 Diabetes
28%
Proportional Hazards Model
14%
All Cause Mortality
14%
Heart Left Ventricle Ejection Fraction
14%
Diarrhea
14%
Estimated Glomerular Filtration Rate
14%
Brain Natriuretic Peptide
14%
Urgent Care
14%
Sodium Glucose Cotransporter
14%
Mineralocorticoid Receptor
14%
Efficacy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Sotagliflozin
100%
Placebo
28%
Maturity Onset Diabetes of the Young
28%
All Cause Mortality
14%
Brain Natriuretic Peptide
14%
Receptor Agonist
14%
Diarrhea
14%
Mineralocorticoid Receptor
14%
Sodium Glucose Cotransporter
14%